Physician profile
Tseday E Sirak
NPI 1346348992
$4,681.08
in general payments reported to CMS, 2019-2025
29 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $278 · 2021: $504 · 2022: $968 · 2023: $598 · 2024: $416 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,207.59 | 2019-2025 | |
| Amgen INC. | $645.60 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $550.68 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $304.33 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $227.19 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $208.00 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.07 | 2019-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.68 | 2019-2024 | Jardiance |
| Heartflow, INC. | $139.53 | 2024-2025 | |
| Baxter Healthcare | $118.40 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Esperion Therapeutics, INC. | $109.53 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $97.14 | 2023-2024 | Inpefa |
| Abbott Laboratories | $96.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.36 | 2024-2025 | Verquvo, Lagevrio, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $78.52 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $65.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.42 | 2019-2021 | |
| Scpharmaceuticals INC. | $57.08 | 2025 | |
| Amarin Pharma, INC. | $55.63 | 2020-2021 | |
| Medtronic Vascular, INC. | $53.28 | 2019 | |
| Edwards Lifesciences Corporation | $52.67 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Intuitive Surgical, INC. | $43.75 | 2019 | |
| Bridgebio Pharma, INC. | $21.52 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $19.44 | 2024 | Onpattro |
| Boston Scientific Corporation | $17.51 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.27 | 2023 | Arcalyst |
| Abiomed | $15.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.33 | 2019 | |
| Lantheus Medical Imaging, INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tseday Sirak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.